Search research articles
Contact Us
Filters
Showing results (171-180 of 181) with videos related to
Page
of 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2026
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Solid Tumors: Primary Analysis of All Tumor-Histology Baskets of the Phase II Randomized EXTEND Trial
Alexander D Sherry, Cara Haymaker, Shuqi Wang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 21, 2022
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation
Eugene J Koay, Mohamed Zaid, Maureen Aliru, et al.
Journal of Hematology & Oncology
|
April 17, 2025
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma
Mahmoud Yousef, Abdelrahman Yousef, Mark W Hurd, et al.
JCO Precision Oncology
|
March 6, 2025
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group
Lakshmi Rajdev, Gentry G King, Christopher H Lieu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2024
Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial
Ethan B Ludmir, Alexander D Sherry, Bryan M Fellman, et al.
The Lancet. Oncology
|
December 1, 2023
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial
Cullen M Taniguchi, Jessica M Frakes, Todd A Aguilera, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
Stephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.
Journal for Immunotherapy of Cancer
|
March 20, 2020
Phase 2 study of pembrolizumab in patients with advanced rare cancers
Aung Naing, Funda Meric-Bernstam, Bettzy Stephen, et al.
Nature Medicine
|
January 19, 2023
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
Timothy A Yap, Naval Daver, Mikhila Mahendra, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 181) with videos related to
Sort By:
Page
of 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2026
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Solid Tumors: Primary Analysis of All Tumor-Histology Baskets of the Phase II Randomized EXTEND Trial
Alexander D Sherry, Cara Haymaker, Shuqi Wang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 21, 2022
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation
Eugene J Koay, Mohamed Zaid, Maureen Aliru, et al.
Journal of Hematology & Oncology
|
April 17, 2025
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma
Mahmoud Yousef, Abdelrahman Yousef, Mark W Hurd, et al.
JCO Precision Oncology
|
March 6, 2025
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group
Lakshmi Rajdev, Gentry G King, Christopher H Lieu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2024
Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial
Ethan B Ludmir, Alexander D Sherry, Bryan M Fellman, et al.
The Lancet. Oncology
|
December 1, 2023
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial
Cullen M Taniguchi, Jessica M Frakes, Todd A Aguilera, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
Stephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.
Journal for Immunotherapy of Cancer
|
March 20, 2020
Phase 2 study of pembrolizumab in patients with advanced rare cancers
Aung Naing, Funda Meric-Bernstam, Bettzy Stephen, et al.
Nature Medicine
|
January 19, 2023
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
Timothy A Yap, Naval Daver, Mikhila Mahendra, et al.
Page
of 19